Engineers from USC and UCLA have developed a wireless, AI-driven spinal implant that delivers smart, real-time pain relief.

According to a new comprehensive report from The Insight Partners, the electrotherapy systems market is witnessing ...

The global Spinal Cord Stimulator Market is estimated to be valued at USD 3,011.0 million in 2025 and is projected to reach USD 5,291.4 million by 2035, registering a compound annual growth rate (CAGR ...

Abbott, a medical devices and health care company, won gold for its Eterna spinal cord stimulation system within the Chronic Conditions Treatment Solutions category at the 2025 Edison Awards, an ...

ABBOTT PARK, Ill., Jan. 30, 2025 – Abbott announced new four-year data showing the long-term and sustained relief that its proprietary BurstDR™ spinal cord stimulation (SCS) technology provides people ...

MONTRÉAL, March 19, 2024 /CNW/ -- Abbott (NYSE: ABT) today announced that the company's Eterna™ SCS system – the smallest implantable, rechargeable spinal cord stimulator (SCS) for the ...

But in recent years, labs have made major strides in innovative techniques that can be applied long after the initial damage to the spinal cord, including using electrical currents to re-awaken ...

On May 16, 2023, the U.S. Food and Drug Administration (FDA) approved spinal cord stimulation (SCS) devices from the pharmaceutical company Abbott to treat chronic back pain in people who have not ...

The FDA approved Abbott Laboratories (NYSE: ABT) spinal cord stimulation (SCS) devices for chronic back pain in people who have not had or are not eligible to receive back surgery, known as ...

(RTTNews) - Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of chronic back ...

Abbott Laboratories ABT said Tuesday that its spinal cord stimulation (SCS) devices were approved by the U.S. Food and Drug Administration to treat people with chronic back pain who aren’t ...

Abbott is putting the old adage that “good things come in threes” to the test, with its fourth FDA approval in less than a year for its spinal cord stimulation (SCS) systems.